Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Plasmacytoma 2Paraproteinemias 2Multiple Myeloma 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Dexamethasone 3filanesib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2pomalidomide 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Gemcitabine 1Calcium Dobesilate 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Plasmacytoma × Injections, Subcutaneous × Other hematologic neoplasm × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡